VANCOUVER, BC / ACCESSWIRE / March 5, 2020 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9) the innovator and pioneer behind neuenergy® is pleased to announce that it has closed on the final tranche of its non-brokered private placement (the "Placement") announced on January 16, 2020 and February 18, 2020, in which it raised proceeds of $518,000.
This final tranche of the Placement consisted of 10,360,000 units (the "Units") of the Company at a price of $0.05 per Unit. Each Unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire an additional common share of the Company at a price of $0.05 until September 5, 2021. In connection with this tranche of the Placement, the Company paid a finder's fee of $700. All securities issued in connection with this tranche of the Placement are subject to a hold period expiring July 6, 2020.
As previously announced, NeutriSci is using the net proceeds of the Placement for production runs and launch of the Company's Dablets™ and Zenstix™ tabs in California, and for general working capital purposes. A corporate update will follow next week.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320
For investor inquiries, please contact investors@neutrisci.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci's is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company's natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberry extract (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
For more information, please visit: www.neutrisci.com.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
SOURCE: NeutriSci International Inc.
View source version on accesswire.com:
https://www.accesswire.com/579382/NeutriSci-Closes-518000-Financing
